Biocentric utilizes an AI-native, disease-agnostic bioplatform to accelerate drug discovery from candidate screening through clinical readiness. The platform combines advanced machine learning with foundational biophysical science to generate novel data and molecules. This approach delivers turnkey solutions for partners across various therapeutic areas with improved accuracy and speed.
Funding
Funding not disclosed
Founders
Product
Problem
Traditional drug discovery processes are lengthy and inefficient, often leading to high failure rates and significant R&D costs. Identifying novel therapeutic candidates with high efficacy and low toxicity requires extensive experimental screening and validation.
Solution
Biocentric accelerates drug discovery by leveraging an AI-native platform that integrates advanced machine learning with biophysical insights. This approach enables the identification and development of novel therapeutic candidates across a range of diseases. The platform provides end-to-end solutions, from initial molecule generation through in silico binding prediction to preclinical validation. By streamlining these early-stage processes, Biocentric aims to deliver breakthrough medicines with enhanced speed and accuracy, ultimately improving patient outcomes.
Target Audience
Biocentric serves pharmaceutical companies, biotechnology firms, and academic research institutions engaged in early-stage drug discovery.
Features
- AI-native platform for in silico drug discovery, covering early-stage pipeline activities.
- Proprietary architectures combined with open-source models and biophysical enhancements for scalable binding prediction.
- Disease-agnostic approach applicable across therapeutic areas including immunology, virology, and neurology.
- Turnkey solutions from molecule generation to preclinical validation.
- Integration of computational biology and biophysical insights to generate novel data and molecules.
- Focus on predictive accuracy and discovery speed to identify high-efficacy, low-toxicity candidates.